Crestline Management, LP

Key Holdings

The portfolio is composed entirely of Denali Therapeutics Inc. (DNLI), a position valued at $49.52 million, representing 100% of the total assets. The firm holds 3.41 million shares of the biotechnology company. While this is the sole remaining position, the firm did reduce its exposure to DNLI during the quarter by 11.7%, a divestment of approximately $4.49 million. Despite this reduction, the decision to retain Denali as the sole holding signals strong confidence in the company's fundamental value or upcoming clinical catalysts. The position is large enough to suggest that Crestline is a significant shareholder, likely holding influence or at least a close watch on the company's operational progress.